case / 14 Sep 2022
Setterwalls has advised IRRAS AB in connection with rights issue of approximately SEK 215 million
Setterwalls has advised IRRAS AB in connection with rights issue of approximately SEK 215 million.
IRRAS AB is medical device company focused on solutions for brain injuries and intracranial bleeding. IRRAS is designing, developing, and commercializing products which improves patient outcomes and reduces the overall cost of care by addressing complications associated with current treatment methods in neurosurgical care. The company’s product portfolio includes the company’s original product, IRRAflow and the Hummingbird ICP Monotoring product line. IRRAS AB is listed on Nasdaq Stockholm.